Ealy diagnosis of tuberous sclerosis in a newborn with opsoclonus: a case report

Main Article Content

Bruno Antunes Contrucci
Gustavo Rogério Pinato
Augusto Oliveira Silva
Bruno Barboza de-Oliveira
Jordana Bueno Resende
Debora de Cássia Tomaz Fernandes
Regina Célia Ajeje Pires de-Albuquerque

Abstract

Classified as a neurocutaneous syndrome, tuberous sclerosis is characterized by the formation of hamartomas, in a multisystemic way, resulting from gene alteration of tumor suppressors. The presence of seizures due to various changes in the central nervous system, hypochromic skin lesions, cardiac rhabdomyomas and, rarely, changes in ocular motricity, are possible phenotypic presentations of tuberous sclerosis. The diagnosis is made based on the presence of clinical criteria and/or genetic testing, usually occurring at preschool age, and is rarely reported in neonates based on clinical signs and symptoms. The authors reported an early diagnosis in a newborn with an unusual initial clinical presentation, which is rarely reported in the literature, with opsoclonus associated with small hypochromic macules. After complementary exams, cardiac nodules, cortical and subcortical tubes were evidenced. Once the diagnosis was confirmed during the
first month of life, it was possible to allow the multidisciplinary and periodic follow-up of the patient, with a direct impact on the quality of life of the entire family context. The management of such a clinical condition depends on a specialized center to meet the psychosocial needs of patients, families and care, in addition to performing regular exams to assess the progression of lesions intrinsic to tuberous sclerosis.

Downloads

Download data is not yet available.
👁 Abstract Views: 53📥 PDF PT (Português (Brasil)) Downloads: 4

Article Details

How to Cite
Bruno Antunes Contrucci, Gustavo Rogério Pinato, Augusto Oliveira Silva, Bruno Barboza de-Oliveira, Jordana Bueno Resende, Debora de Cássia Tomaz Fernandes, & Regina Célia Ajeje Pires de-Albuquerque. (2022). Ealy diagnosis of tuberous sclerosis in a newborn with opsoclonus: a case report. Revista De Pediatria SOPERJ, 22(3), 143–148. https://doi.org/10.31365/issn.2595-1769.v22i2p143-148
Section
Relato de Caso

References

1. Bicas, HEA. Oculomotricidade e seus fundamentos. Arq. Bras. Oftalmol., São Paulo, v. 66, n. 5, p. 687-700, Oct. 2003.

2. Wan MJ, Chan KL, Jastrzembski BG, Ali A. Neuro-ophthalmological manifestations of tuberous sclerosis: current perspectives. Eye Brain. 2019;11:13-23.

3. Northrup H, Aronow ME, Bebin EM, et al. Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations. Pediatr Neurol 2021; 123:50.

4. Gupta A, de Bruyn G, Tousseyn S, et al. Epilepsy and Neurodevelopmental Comorbidities in Tuberous Sclerosis Complex: A Natural History Study. Pediatr Neurol 2020; 106:10.

5. Curatolo P, Moavero R, de Vries PJ. Neurological and neuropsychiatric aspects of tuberous sclerosis complex. Lancet Neurol 2015; 14:733.

6. Farach LS, Pearson DA, Woodhouse JP, et al. Tuberous Sclerosis Complex Genotypes and Developmental Phenotype. Pediatr Neurol. 2019; 96:58.

7. Słowińska M, Kotulska K, Szymańska S, et al. Approach to Preventive Epilepsy Treatment in Tuberous Sclerosis Complex and Current Clinical Practice in 23 Countries. Pediatr Neurol 2021; 115:21.

8. Franz DN, Lawson JA, Yapici Z, et al. Everolimus dosing recommendations for tuberous sclerosis complex-associated refractory seizures. Epilepsia 2018; 59:1188.

9. Amin S, Lux A, Calder N, et al. Causes of mortality in individuals with tuberous sclerosis complex. Dev Med Child Neurol 2017; 59:612.

10. Kotulska K, Kwiatkowski DJ, Curatolo P, et al. Prevention of Epilepsy in Infants with Tuberous Sclerosis Complex in the EPISTOP Trial. Ann Neurol 2021; 89:304.

11. Curatolo P, Nabbout R, Lagae L, et al. Management of epilepsy associated with tuberous sclerosis complex: Updated clinical recommendations. Eur J Paediatr Neurol 2018; 22:738.

12. Thiele EA, Bebin EM, Bhathal H, et al. Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical Trial. JAMA Neurol 2021; 78:285.

13. Giordano F, Moscheo C, Lenge M, et al. Neurosurgical treatment of subependymal giant cell astrocytomas in tuberous sclerosis complex: a series of 44 surgical procedures in 31 patients. Childs Nerv Syst 2020; 36:951.

14. Jeong A, Nakagawa JA, Wong M. Predictors of Drug-Resistant Epilepsy in Tuberous Sclerosis Complex. J Child Neurol 2017; 32:1092.

15. Villar J, Cheikh I, Victora C, Ohuma E, Bertino E, Altman DG, et al. International Fetal and Newborn Growth Consortium for the 21st Century (INTERGROWTH-21st) International standards for newborn weight, length, and head circumference by gestational age and sex: the Newborn Cross-Sectional Study of the INTERGROWTH-21st Project. Lancet. 2014;384:857-68.

Most read articles by the same author(s)